Targeting PCSK9 for Therapeutic Gains

Michael D. Shapiro, Sergio Fazio, Hagai Tavori

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.

Original languageEnglish (US)
JournalCurrent atherosclerosis reports
Issue number4
StatePublished - Apr 2015
Externally publishedYes


  • Lipoprotein (a)
  • Low-density lipoprotein
  • Low-density lipoprotein receptor
  • Pleiotropic effects
  • Proprotein convertase subtilisin kexin 9
  • Triglycerdies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Targeting PCSK9 for Therapeutic Gains'. Together they form a unique fingerprint.

Cite this